REFERENCES

1. Armani-Tourret M, Bone B, Tan TS, et al. Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure. Nat Rev Microbiol. 2024;22:328-44.

2. Veenhuis RT, Abreu CM, Costa PAG, et al. Monocyte-derived macrophages contain persistent latent HIV reservoirs. Nat Microbiol. 2023;8:833-44.

3. Barbehenn A, Shi L, Shao J, et al. Rapid biphasic decay of intact and defective HIV DNA reservoir during acute treated HIV disease. Nat Commun. 2024;15:9966.

4. Jin J, Bai H, Yan H, et al. PRMT2 promotes HIV-1 latency by preventing nucleolar exit and phase separation of Tat into the Super Elongation Complex. Nat Commun. 2023;14:7274.

5. León-Rivera R, Morsey B, Niu M, Fox HS, Berman JW. Interactions of monocytes, HIV, and ART identified by an innovative scRNAseq pipeline: pathways to reservoirs and HIV-associated comorbidities. mBio. 2020;11:e01037-20.

6. Nixon CC, Mavigner M, Sampey GC, et al. Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo. Nature. 2020;578:160-5.

7. McBrien JB, Mavigner M, Franchitti L, et al. Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8⁺ cells. Nature. 2020;578:154-9.

8. Board NL, Moskovljevic M, Wu F, Siliciano RF, Siliciano JD. Engaging innate immunity in HIV-1 cure strategies. Nat Rev Immunol. 2022;22:499-512.

9. Wu L, Zheng Z, Xun J, et al. Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a “shock and kill” strategy for ART-free virological control: a phase II single-arm study. Signal Transduct Target Ther. 2024;9:231.

10. Covino DA, Desimio MG, Doria M. Impact of IL-15 and latency reversing agent combinations in the reactivation and NK cell-mediated suppression of the HIV reservoir. Sci Rep. 2022;12:18567.

11. Okoye AA, Fromentin R, Takata H, et al. The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription. PLoS Pathog. 2022;18:e1010245.

12. Peng W, Hong Z, Chen X, et al. Thiostrepton reactivates latent HIV-1 through the p-TEFb and NF-κB pathways mediated by heat shock response. Antimicrob Agents Chemother. 2020;64:e02328-19.

13. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977.

14. Wu CY, Yang YH, Lin YS, et al. The effect and mechanism of astragalus polysaccharides on T cells and macrophages in inhibiting prostate cancer. Biomed J. 2025;48:100741.

15. Zhang Q, Su C, Luo Y, et al. Astragalus polysaccharide enhances antitumoral effects of chimeric antigen receptor- engineered (CAR) T cells by increasing CD122⁺CXCR3⁺PD-1^- memory T cells. Biomed Pharmacother. 2024;179:117401.

16. Zhang Y, Ji W, Qin H, et al. Astragalus polysaccharides alleviate DSS-induced ulcerative colitis in mice by restoring SCFA production and regulating Th17/Treg cell homeostasis in a microbiota-dependent manner. Carbohydr Polym. 2025;349:122829.

17. Cunha E Rocha K, Ying W, Olefsky JM. Exosome-mediated impact on systemic metabolism. Annu Rev Physiol. 2024;86:225-53.

18. Miyazaki K, Wada Y, Okuno K, et al. An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer. Mol Cancer. 2023;22:2.

19. Salunkhe S, Dheeraj , Basak M, Chitkara D, Mittal A. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: Strategies and significance. J Control Release. 2020;326:599-614.

20. Wang Q, Guo W, Niu L, et al. 3D-hUMSCs exosomes ameliorate vitiligo by simultaneously potentiating treg cells-mediated immunosuppression and suppressing oxidative stress-induced melanocyte damage. Adv Sci. 2024;11:e2404064.

21. Chen J, Li C, Li R, Chen H, Chen D, Li W. Exosomes in HIV infection. Curr Opin HIV AIDS. 2021;16:262-70.

22. X.，H. Lu，M. Dooner,et al. Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes. JCI Insight. 2018;3:e95676.

23. Okoye I, Xu L, Oyegbami O, et al. Plasma extracellular vesicles enhance HIV-1 infection of activated CD4⁺ T cells and promote the activation of latently infected J-Lat10.6 cells via miR-139-5p transfer. Front Immunol. 2021;12:697604.

24. Montaldo C, Terri M, Riccioni V, et al. Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response. J Hepatol. 2021;75:1301-11.

25. Liu B, Xian Y, Shen T, et al. Targeted blockage of pathological extracellular vesicles and particles from fibroblast-like synoviocytes for osteoarthritis relief: proteomic analysis and cellular effect. J Extracell Vesicles. 2025;14:e70162.

26. Xia T, Yin H, Zhu Q, et al. DDX5 super-enhancer promotes vasculogenic mimicry formation and metastasis in nasopharyngeal carcinoma by enhancing ADAM10 transcription. Cell Rep Med. 2025;6:102146.

27. Zhang C, Pang B, Luo Y, et al. Targeting the galectin-7/TRPM2/Zn²⁺/DRP-1 signaling pathway: a potential therapeutic intervention in the pathogenesis of SJS/TEN. Allergy. 2025;80:1358-76.

28. Mao X, Cai T, Olyarchuk JG, Wei L. Automated genome annotation and pathway identification using the KEGG Orthology (KO) as a controlled vocabulary. Bioinformatics. 2005;21:3787-93.

29. Li W, Wang X, Li C, Chen T, Yang Q. Exosomal non-coding RNAs: emerging roles in bilateral communication between cancer cells and macrophages. Mol Ther. 2022;30:1036-53.

30. Ashokkumar M, Mei W, Peterson JJ, et al. Integrated single-cell multiomic analysis of HIV latency reversal reveals novel regulators of viral reactivation. Genomics Proteomics Bioinformatics. 2024;22:qzae003.

31. Dias MVS, Costa CS, daSilva LLP. The ambiguous roles of extracellular vesicles in HIV replication and pathogenesis. Front Microbiol. 2018;9:2411.

32. Nolte-’t Hoen E, Cremer T, Gallo RC, Margolis LB. Extracellular vesicles and viruses: are they close relatives? Proc Natl Acad Sci U S A. 2016;113:9155-61.

33. Yu W, Hurley J, Roberts D, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32:466-77.

34. Yao J, Wang Z, Cheng Y, et al. M2 macrophage-derived exosomal microRNAs inhibit cell migration and invasion in gliomas through PI3K/AKT/mTOR signaling pathway. J Transl Med. 2021;19:99.

35. Lu N, Min J, Peng L, et al. MiR-297 inhibits tumour progression of liver cancer by targeting PTBP3. Cell Death Dis. 2023;14:564.

36. Li X, Zhou W, Li Z, Guan F. Hsa_circ_0056558 regulates cyclin-dependent kinase 6 by sponging microRNA-1290 to suppress the proliferation and differentiation in ankylosing spondylitis. Autoimmunity. 2021;54:114-28.

37. Song T, Xu A, Zhang Z, et al. CircRNA hsa_circRNA_101996 increases cervical cancer proliferation and invasion through activating TPX2 expression by restraining miR-8075. J Cell Physiol. 2019;234:14296-305.

38. Hu W, Wang W, Chen Z, Chen Y, Wang Z. Engineered exosomes and composite biomaterials for tissue regeneration. Theranostics. 2024;14:2099-126.

39. Panagoulias I, Karagiannis F, Aggeletopoulou I, et al. Ets-2 acts as a transcriptional repressor of the human immunodeficiency virus type 1 through binding to a repressor-activator target sequence of 5’-LTR. Front Immunol. 2017;8:1924.

40. Wan C, Yan S, Lu R, et al. Astragalus polysaccharide improves immunogenicity of influenza vaccine as well as modulate gut microbiota in BALB/c mice. Microb Pathog. 2024;195:106893.

41. Zhao D, Chen X, Wang L, et al. Bidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine. Int J Biol Macromol. 2023;234:123635.

42. Zhou L, Liu Z, Wang Z, et al. Astragalus polysaccharides exerts immunomodulatory effects via TLR4-mediated MyD88-dependent signaling pathway in vitro and in vivo. Sci Rep. 2017;7:44822.

43. Zhong Y, Xiao Q, Kang Z, et al. Astragalus polysaccharide alleviates ulcerative colitis by regulating the balance of Tfh/Treg cells. Int Immunopharmacol. 2022;111:109108.

44. Cillo AR, Sobolewski MD, Bosch RJ, et al. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2014;111:7078-83.

45. Meng W, He C, Hao Y, Wang L, Li L, Zhu G. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Deliv. 2020;27:585-98.

46. Arenaccio C, Chiozzini C, Columba-Cabezas S, et al. Exosomes from human immunodeficiency virus type 1 (HIV-1)-infected cells license quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef- and ADAM17-dependent mechanism. J Virol. 2014;88:11529-39.

47. Okkenhaug K. Rules of engagement: distinct functions for the four class I PI3K catalytic isoforms in immunity. Ann N Y Acad Sci. 2013;1280:24-6.

48. Cao M, Lai P, Liu X, et al. ATF5 promotes malignant T cell survival through the PI3K/AKT/mTOR pathway in cutaneous T cell lymphoma. Front Immunol. 2023;14:1282996.

49. Pardons M, Cole B, Lambrechts L, et al. Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoir. Nat Commun. 2023;14:8397.

50. Hokello J, Lakhikumar Sharma A, Tyagi M. AP-1 and NF-κB synergize to transcriptionally activate latent HIV upon T-cell receptor activation. FEBS Lett. 2021;595:577-94.

51. Williams SA, Greene WC. Regulation of HIV-1 latency by T-cell activation. Cytokine. 2007;39:63-74.

52. Mbonye U, Karn J. The molecular basis for human immunodeficiency virus latency. Annu Rev Virol. 2017;4:261-85.

53. Cotto KC, Wagner AH, Feng YY, et al. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res. 2018;46:D1068-73.

54. Dutilleul A, Rodari A, Van Lint C. Depicting HIV-1 transcriptional mechanisms: a summary of what we know. Viruses. 2020;12:1385.

55. Mbonye U, Karn J. Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology. 2014;454-5:328-39.